de-identified claims data from optum's de-identified clinformatics data mart database (cdm) (Optum Inc)
90
Structured Review
Optum Inc
de-identified claims data from optum's de-identified clinformatics data mart database (cdm)
De Identified Claims Data From Optum's De Identified Clinformatics Data Mart Database (Cdm), supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/claims+data+from+optum%E2%80%99s+clinformatics+data+mart+(cdm)/de+identified+clinformatics+data+mart+database/pmc10167987-59-6-10
Average 90 stars, based on 1 article reviews
De Identified Claims Data From Optum's De Identified Clinformatics Data Mart Database (Cdm), supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/claims+data+from+optum%E2%80%99s+clinformatics+data+mart+(cdm)/de+identified+clinformatics+data+mart+database/pmc10167987-59-6-10
Average 90 stars, based on 1 article reviews
de-identified claims data from optum's de-identified clinformatics data mart database (cdm) - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Association of Cardiovascular Outcomes with Low-Dose Glucocorticoid Use in Patients with Rheumatoid Arthritis. Article Snippet: Objective.. Many guidelines recommend limiting glucocorticoids in patients with rheumatoid arthritis (RA), but 40% of patients remain on glucocorticoids long-term.. We evaluated the cardiovascular risk of long-term glucocorticoid use by studying patients on stable disease modifying anti-rheumatic drugs (DMARDs). Article Title: Newer GLP-1 RAs Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: a Population-Level Time Series Analysis. Article Snippet: This was a retrospective population-level time series analysis that used administrative insurance claims data from Article Title: Clinical burden and healthcare resource utilization associated with achondroplasia: a real-world observational, retrospective cohort study Article Snippet: This longitudinal retrospective cohort study used data from Article Title: Varying definitions of long-term opioid therapy: examining prevalence, prescription patterns, and substance-related adverse outcomes. Article Snippet: Patrick D. Quinn , PhD�, Olena Mazurenko , MD, PhD, Richard Meraz, MS, Zheng Chang, PhD, Toyya A. Pujol, PhD, Adam T. Hirsh, PhD, Arvid Sj€ olander , PhD, Kurt Kroenke , MD, Brian M. D’Onofrio, PhD Department of Applied Health Science, School of Public Health, Indiana University, Bloomington, IN 47405, United States Department of Health Policy and Management, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN 46202, United States Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN 47405, United States Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden RAND Corporation, Arlington, VA 22202, United States Department of Psychology, Indiana University, Indianapolis, IN 46202, United States Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States Regenstrief Institute, Indianapolis, IN 46202, United States �Corresponding author: Department of Applied Health Science, School of Public Health, Indiana University, 1025 E. 7th St, Room 116, Bloomington, IN 47405, United States.. Email: Quinnp@iu.edu Article Title: Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients Article Snippet: Claims data from Article Title: Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients. Article Snippet: Aim: To evaluate the real-world incidence of cardiovascular adverse events (CVAE) and clinical outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with covalent Bruton’s Tyrosine Kinase inhibitors (cBTKis).. Methods: Patients initiating cBTKi treatment from 1 January 2020 to 1 January 2023 were identified using claims data.. Demographics, first-line (1L) and second-line or later (2L+) therapy, incident CVAEs, and clinical outcomes were assessed. Article Title: Monitoring and treatment patterns of von Hippel-Lindau disease-associated central nervous system hemangioblastomas. Article Snippet: Data Source Administrative claims data from 2007 to 2020 from Derivative Assay:Article Title: Real-World Switch Rates, Treatment Patterns, and Healthcare Costs Among Patients With Spasticity Treated With Botulinum Toxins. Article Snippet: .. This analysis used administrative claims data from Optum’s de-identified |